CA2691632A1 - Carbostyril derivatives including cilostazol for treating fatty liver - Google Patents

Carbostyril derivatives including cilostazol for treating fatty liver Download PDF

Info

Publication number
CA2691632A1
CA2691632A1 CA002691632A CA2691632A CA2691632A1 CA 2691632 A1 CA2691632 A1 CA 2691632A1 CA 002691632 A CA002691632 A CA 002691632A CA 2691632 A CA2691632 A CA 2691632A CA 2691632 A1 CA2691632 A1 CA 2691632A1
Authority
CA
Canada
Prior art keywords
fatty liver
medicament
preventing
treating fatty
cilostazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002691632A
Other languages
English (en)
French (fr)
Inventor
Atsushi Nakajima
Koji Fujita
Masato Yoneda
Osamu Mukeda
Takako Ichimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2691632A1 publication Critical patent/CA2691632A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002691632A 2007-07-11 2008-07-09 Carbostyril derivatives including cilostazol for treating fatty liver Abandoned CA2691632A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007181760 2007-07-11
JP2007-181760 2007-07-11
PCT/JP2008/062771 WO2009008539A1 (en) 2007-07-11 2008-07-09 Carbostyril derivatives including cilostazol for treating fatty liver

Publications (1)

Publication Number Publication Date
CA2691632A1 true CA2691632A1 (en) 2009-01-15

Family

ID=39689465

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002691632A Abandoned CA2691632A1 (en) 2007-07-11 2008-07-09 Carbostyril derivatives including cilostazol for treating fatty liver

Country Status (9)

Country Link
US (2) US8642618B2 (enExample)
EP (1) EP2162134A1 (enExample)
JP (2) JP5558348B2 (enExample)
KR (2) KR20150038739A (enExample)
CN (1) CN101778630A (enExample)
AR (1) AR067446A1 (enExample)
CA (1) CA2691632A1 (enExample)
TW (1) TW200908973A (enExample)
WO (1) WO2009008539A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101094934B1 (ko) * 2010-10-22 2011-12-15 영남대학교 산학협력단 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물
EP3263705A1 (en) * 2016-06-28 2018-01-03 DKFZ Deutsches Krebsforschungszentrum Treatments of non-alcoholic steatohepatitis (nash)
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
WO2022240783A1 (en) * 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Methods of treating liver diseases with phosphodiesterase 3b (pde3b) inhibitors
AU2022339755A1 (en) * 2021-08-31 2024-02-22 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with camp responsive element binding protein 3 like 3 (creb3l3) inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3944257B2 (ja) * 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤

Also Published As

Publication number Publication date
US20110039887A1 (en) 2011-02-17
US8642618B2 (en) 2014-02-04
KR20100046188A (ko) 2010-05-06
WO2009008539A1 (en) 2009-01-15
CN101778630A (zh) 2010-07-14
JP5558348B2 (ja) 2014-07-23
KR20150038739A (ko) 2015-04-08
JP2014185161A (ja) 2014-10-02
US20140121241A1 (en) 2014-05-01
JP2010533166A (ja) 2010-10-21
AR067446A1 (es) 2009-10-14
EP2162134A1 (en) 2010-03-17
TW200908973A (en) 2009-03-01

Similar Documents

Publication Publication Date Title
US20140121241A1 (en) Carbostyril Derivatives Including Cilostazol for Treating Fatty Liver
CN101754758B (zh) 一种用于治疗阿尔茨海默氏症的包含喹诺酮衍生物和多奈哌齐的药物
US9487534B2 (en) Modulators of virus assembly as antiviral agents
US20150292045A1 (en) Alternative uses for hbv assembly effectors
EP3992183A1 (en) Method for treating idiopathic pulmonary fibrosis
EP2870161B1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
SK7502002A3 (en) Pharmaceutical combinations
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
US20250064886A1 (en) Cardiovascular and cerebrovascular drug and use thereof
CN101631538B (zh) 用于治疗慢性阻塞性肺病的药物
WO2004075895A1 (ja) 眼圧低下剤
KR101632448B1 (ko) 카르보스티릴 및 카르니틴의 조합물
WO2025135087A1 (ja) 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物
US20040048776A1 (en) Medicament for preventive and therapeutic treatment of fibrosis
KR20250092218A (ko) 인슐린 저항성 및 연관 장애의 치료 방법
HK1140136B (en) A medicament for treating chronic obstructive pulmonary disease
WO2006051757A1 (ja) 虚血性心疾患もしくは虚血性心筋症の治療剤または予防剤
JPH09194360A (ja) 肝線維化防止剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130618

FZDE Dead

Effective date: 20160608